TMDX

TransMedics Group, Inc. Common Stock

TMDX
Closed
$71.42
Closed
-(-)

At close

Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply

About

TransMedics Group, Inc. operates as a commercial stage medical technology company. The company is headquartered in Andover, Massachusetts and currently employs 898 full-time employees. The company went IPO on 2019-05-02. The firm specializes in portable extracorporeal warm perfusion and assessment of donor organs for transplantation. Its Organ Care System (OCS) is a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside the human body. The company also developed its National OCS Program (NOP), which is a turnkey solution to provide outsourced organ procurement, OCS perfusion management and transplant logistics services, to provide transplant programs in the United States. Its logistics services include aviation transportation and other coordination activities. Its NOP provides trained organ procurement surgeons, clinical specialists and transplant coordinators that provide an end-to-end clinical solution using its OCS technology.
Country

US

CEO

Dr. Waleed Hassanein

IPO date

2019

Employees

898

ISIN

US89377M1099

Key stats

Open

$72.16

Volume

637.78K

Market cap

$2.49B

Prev. close

$72.19

Impl / hst vl

-

Open interest

$0.00

$70.23

Day’s Range

$73.30

$60.11

52W Range

$151.85

Valuation

55
Valuation score
Fairly Valued
P/E
14.66
P/S
3.96
P/B
5.10
Current ratio
6.74
Debt / Equity
0.80
ROE
41.92%
Gross margin
58.16%
Income growth
-93.06%
FCF growth
-163.81

Analysts estimates

Consensus rating
Buy

The average rating from top 9 analysts indicates that stock is expected to perform in line with the market

Str. Sell
Sell
Hold
Buy
Str. Buy
Avg. price target
$125.56
The top 13 analysts forecasts that 12-month price may increase by 75.81%, with a low of $80.80 and a high of $149.10
$80.80
Low
$125.56
Avg
$149.10
High
Current price

Earnings

Q1 ‘26 revenue
$173.93M
Q1 ‘26 net income
$7.32M
Revenue
Net income
Previous EPS
$0.30
Estimate EPS
$0.53
Actual EPS
Estimate EPS
Financial advisor consultation illustration
Get professional financial guidance

Schedule your free first call with a financial advisor on CUSP Wealth
*T&Cs apply